|Bid||1,023.60 x 900|
|Ask||1,024.65 x 900|
|Day's Range||1,019.80 - 1,024.65|
|52 Week Range||1,009.85 - 1,053.25|
|Beta (3Y Monthly)||0.93|
|PE Ratio (TTM)||302.52|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The global science and technology company beat expectations in Q1. However, a pending acquisition caused Danaher to cut its full-year outlook.
biopharma healthcare business offset revenue. On an adjusted basis, the company earned $1.07 a share, above the 99 cents posted a year ago and the $1.02 a share forecast by analyst surveyed by FactSet. Revenue increased to $4.9 billion from $4.7 billion in the same period in 2018, with non-GAAP core revenue growth of 5.5%.
On a per-share basis, the Washington-based company said it had net income of 46 cents. Earnings, adjusted for pretax expenses and amortization costs, were $1.07 per share. The results exceeded Wall Street ...
General Electric shareholders aren’t the only ones benefiting from the American industrial giant’s transformation under CEO Larry Culp.
Here's how and why the best-performing stocks in the industrial-goods sector made headway in the last year, and what to expect in the future.